Guggenheim's Longstanding Pfizer Ties Tested Amid Starboard Battle
Portfolio Pulse from Vandana Singh
A power struggle has emerged between Pfizer and activist investor Starboard Value, with Guggenheim Partners caught in the middle. Starboard, holding a $1 billion stake, criticizes Pfizer's acquisitions and capital allocation, leading to a 50% stock drop from its peak. Former Pfizer executives reversed their support for Starboard, backing current CEO Albert Bourla. Guggenheim, a long-time advisor to Pfizer, is entangled in the dispute, while Pfizer turns to PJT Partners for defense.
October 16, 2024 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer is in a power struggle with Starboard Value, which criticizes its acquisitions and capital allocation, leading to a 50% stock drop. Former executives reversed their support for Starboard, backing CEO Bourla. Pfizer has turned to PJT Partners for defense.
The ongoing dispute with Starboard Value and criticism over acquisitions have negatively impacted Pfizer's stock, which has dropped significantly. The reversal of support by former executives adds to the uncertainty, and the shift to PJT Partners indicates a strategic defense move.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100